On December 1, 2025 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO (Free ESMO Whitepaper) Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details:
Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20
Mutant NSCLC: Randomized Dose Optimization
Presentation Number: 981P
Session Type and Title: Poster Display session and cocktail
Session Date & Time: Friday, December 5, 2025; 5:15 – 6:15 p.m. SGT
Full abstracts are available for public viewing via the ESMO (Free ESMO Whitepaper) Asia Congress website.
Conference Call and Webcast Details
In conjunction with the ESMO (Free ESMO Whitepaper) Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
(Press release, ORIC Pharmaceuticals, DEC 1, 2025, View Source [SID1234661021])